About Myostin Therapeutics

About company

Myostin is a biotechnology company that has acquired the intellectual property (IP) assets for novel ways to improve muscle function and induce muscle growth. The company was formed by Dr Kevin Healey specifically to develop and exploit this IP for human therapeutic purposes. Myostin’s primary focus is to develop a drug to treat Duchenne Muscular Dystrophy (DMD) using its unique myostatin antagonist technology.